A merger between California-based Synopsys and Pennsylvania-based Ansys is facing delays due to a review by China's State Administration for Market Regulation, the Financial Times reported June 12, citing two people with knowledge of the matter.
While the $35 billion deal has been approved in the US and Europe and was expected to close soon, US President Donald Trump's recent chip export controls against China have complicated the approval process in Beijing, the report said.
The new restrictions have reportedly introduced complexities, potentially prolonging SAMR's review process from the original 180-day schedule.
Synopsys is actively working with the Chinese regulator to address concerns and still aims to close the deal "in the first half of this year," the FT reported, citing Synopsys CEO Sassine Ghazi during an earnings call in May.
(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.